Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
otviciclib
- Development stage
- Preclinical
- Lead developer
- Vichem Chemie Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Otviciclib is a preclinical-stage, orally bioavailable small molecule drug candidate developed by Vichem Chemie Research in partnership with the Medical University of Innsbruck. It functions as a broad-spectrum cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK1, CDK2, CDK3, CDK5, CDK9, and CDK16, while also inhibiting the WNT signaling pathway. Identified through phenotypic assays that simulate the tumor microenvironment, otviciclib has demonstrated the ability to kill cancer stem cells and tumor cells with low nanomolar potency. It is currently being investigated for the treatment of multiple myeloma and various solid tumors, including colorectal cancer, glioblastoma, and atypical teratoid/rhabdoid tumors (ATRT).
- Other names
- Myeloma/CDK program
02
Targets
CDK1 (Cyclin-dependent kinase 1)CDK16CDK2 (Cyclin-dependent kinase 2)CDK3 (Cyclin-dependent kinase 3)CDK5 (Cyclin-dependent kinase 5)CDK7CDK9 (Cyclin-dependent kinase 9)MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on otviciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on otviciclib.